CA2068320A1 - Production d'un inhibiteur recombinant de l'interleukine-1 humaine - Google Patents

Production d'un inhibiteur recombinant de l'interleukine-1 humaine

Info

Publication number
CA2068320A1
CA2068320A1 CA2068320A CA2068320A CA2068320A1 CA 2068320 A1 CA2068320 A1 CA 2068320A1 CA 2068320 A CA2068320 A CA 2068320A CA 2068320 A CA2068320 A CA 2068320A CA 2068320 A1 CA2068320 A1 CA 2068320A1
Authority
CA
Canada
Prior art keywords
inhibitor
production
recombinant human
human interleukin
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2068320A
Other languages
English (en)
Other versions
CA2068320C (fr
Inventor
Robert Hageman
Stephen P. Eisenberg
David Dripps
Ronald Evans
Henryk Cudny
Robert C. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Robert Hageman
Stephen P. Eisenberg
David Dripps
Ronald Evans
Henryk Cudny
Robert C. Thompson
Synergen, Inc.
Amgen Boulder Inc.
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert Hageman, Stephen P. Eisenberg, David Dripps, Ronald Evans, Henryk Cudny, Robert C. Thompson, Synergen, Inc., Amgen Boulder Inc., Amgen Inc. filed Critical Robert Hageman
Publication of CA2068320A1 publication Critical patent/CA2068320A1/fr
Application granted granted Critical
Publication of CA2068320C publication Critical patent/CA2068320C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédé de production de quantités commerciales d'inhibiteur d'interleukine-1 hautement purifiée (IL-1i) à partir d'un hôte recombiné. Un hôte de E. coli recombiné préféré utilisé dans ce procédé est également décrit.
CA002068320A 1989-11-29 1990-11-29 Production d'un inhibiteur recombinant de l'interleukine-1 humaine Expired - Lifetime CA2068320C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44265289A 1989-11-29 1989-11-29
US442,652 1989-11-29
PCT/US1990/006979 WO1991008285A1 (fr) 1989-11-29 1990-11-29 Production d'inhibiteur d'interleukine-1 humaine recombinee

Publications (2)

Publication Number Publication Date
CA2068320A1 true CA2068320A1 (fr) 1991-05-30
CA2068320C CA2068320C (fr) 2000-10-17

Family

ID=23757611

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002068320A Expired - Lifetime CA2068320C (fr) 1989-11-29 1990-11-29 Production d'un inhibiteur recombinant de l'interleukine-1 humaine

Country Status (17)

Country Link
US (1) US5453490A (fr)
EP (1) EP0502956B1 (fr)
JP (1) JP3014007B2 (fr)
KR (1) KR0182819B1 (fr)
AT (1) ATE152172T1 (fr)
AU (1) AU651955B2 (fr)
BR (1) BR9007883A (fr)
CA (1) CA2068320C (fr)
DE (1) DE69030582T2 (fr)
DK (1) DK0502956T3 (fr)
ES (1) ES2103305T3 (fr)
FI (1) FI104733B (fr)
GR (1) GR3024031T3 (fr)
HK (1) HK1006856A1 (fr)
HU (1) HUT64582A (fr)
NO (1) NO305290B1 (fr)
WO (1) WO1991008285A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) * 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) * 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5861476A (en) * 1994-02-02 1999-01-19 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5981713A (en) * 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5837495A (en) * 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
IT1270662B (it) * 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JP4771563B2 (ja) * 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
ATE549033T1 (de) 2002-09-06 2012-03-15 Amgen Inc Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
TR201816556T4 (tr) 2004-04-02 2018-11-21 Swedish Orphan Biovitrum Ab Publ Il-1ra agregasyonunun azaltilmasina yöneli̇k yöntemler
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US20070248653A1 (en) * 2006-04-20 2007-10-25 Cochrum Kent C Hemostatic compositions and methods for controlling bleeding
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JP5894364B2 (ja) * 2007-08-16 2016-03-30 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼および付属器組織の炎症を処置するための治療組成物
WO2009062339A1 (fr) 2007-11-14 2009-05-22 General Regeneratives, Ltd. Procédés d'utilisation d'un antagoniste des récepteurs de l'interleukine 1 en tant qu'un agent myéloprotecteur
EP2259774B1 (fr) 2008-02-27 2012-12-12 Biomet Biologics, LLC Procédés et compositions pour administrer un antagoniste de récepteur d interleukine-1antagonist
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
CN107337735B (zh) 2010-07-29 2021-06-22 巴扎德制药公司 嵌合il-1受体i型激动剂和拮抗剂
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
SG10201606218WA (en) * 2011-07-29 2016-09-29 Eleven Biotherapeutics Inc Purified Proteins
WO2013170636A1 (fr) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 Protéine et conjugué protéique pour le traitement du diabète et applications associées
BR112015022587A2 (pt) 2013-03-13 2017-10-24 Eleven Biotherapeutics Inc formulações de citocina quimérica para entrega ocular
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9758806B2 (en) * 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
WO2015067791A1 (fr) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Promédicaments à bae de relaxine
EP3074507B1 (fr) 2013-11-26 2022-01-05 Biomet Biologics, LLC Procédés de médiation des phénotypes macrophagiques
WO2015191783A2 (fr) 2014-06-10 2015-12-17 Abbvie Inc. Biomarqueurs des maladies inflammatoires et leurs procédés d'utilisation
WO2018022982A1 (fr) 2016-07-29 2018-02-01 Trustees Of Boston University L'hématopoïèse clonale associée à l'âge accélère le développement d'une maladie cardio-métabolique
US11285196B2 (en) 2017-03-13 2022-03-29 Eslam Abbas Baseuny Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
EP3836954A1 (fr) 2018-08-13 2021-06-23 Iltoo Pharma Combinaison d'interleukine 2 et d'un inhibiteur de l'interleukine 1, conjugués et utilisations thérapeutiques de celle-ci
WO2023222565A1 (fr) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Procédés d'évaluation de l'épuisement de cellules souches hématopoïétiques induites par une inflammation chronique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0138654B1 (ko) * 1987-08-26 1998-04-30 프레드릭 에이. 유스티스, 3세 인터루킨-i 저해제 및 이의 제조방법
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1991017184A1 (fr) * 1990-04-27 1991-11-14 The Upjohn Company Inhibiteurs ameliores d'interleukine-1
DE69131044T2 (de) * 1990-05-01 1999-11-18 Chiron Corp Interleukin-i antagonist und seine verwendung

Also Published As

Publication number Publication date
BR9007883A (pt) 1992-09-29
HU9201777D0 (en) 1992-12-28
JPH05503007A (ja) 1993-05-27
ES2103305T3 (es) 1997-09-16
KR920703792A (ko) 1992-12-18
DE69030582T2 (de) 1998-06-25
EP0502956A4 (en) 1992-12-09
GR3024031T3 (en) 1997-10-31
EP0502956A1 (fr) 1992-09-16
FI922434A0 (fi) 1992-05-27
NO305290B1 (no) 1999-05-03
DE69030582D1 (de) 1997-05-28
WO1991008285A1 (fr) 1991-06-13
DK0502956T3 (da) 1997-10-20
HUT64582A (en) 1994-01-28
EP0502956B1 (fr) 1997-04-23
FI104733B (fi) 2000-03-31
ATE152172T1 (de) 1997-05-15
AU651955B2 (en) 1994-08-11
CA2068320C (fr) 2000-10-17
NO922138L (no) 1992-05-29
FI922434A (fi) 1992-05-27
HK1006856A1 (en) 1999-03-19
US5453490A (en) 1995-09-26
KR0182819B1 (en) 1999-04-01
NO922138D0 (no) 1992-05-29
AU6900791A (en) 1991-06-26
JP3014007B2 (ja) 2000-02-28

Similar Documents

Publication Publication Date Title
CA2068320A1 (fr) Production d'un inhibiteur recombinant de l'interleukine-1 humaine
AU5978190A (en) Controller of refrigerating plant
EP1133995A3 (fr) Inhibiteurs de l'interleukine-1
AU2783889A (en) Irrigation controller
AU5974290A (en) Novel peptidase inhibitors
AU4019289A (en) Hiv protease inhibitors useful for the treatment of aids
AU1928388A (en) Surgical dressing
AU627937B2 (en) Inhibitors of retroviral proteases
AU1928688A (en) Tissue factor inhibitor
AU570133B2 (en) Hand surgery table
AU7817387A (en) Purification of recombinant tumor necrosis factor
AU4093389A (en) Purification of 2,2-dichloro-1,1,1-trifluoroethane
AU6880291A (en) Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
AU6643690A (en) Polypeptide inhibitors of gamma interferon
AU1097988A (en) Alkylmelatonins
AU3094289A (en) Treatment of abnormal bone conditions using interleukin-6
AU5088690A (en) Keratoconjunctivitis cytotoxin and methods for its use and production
AU3040684A (en) L-amino acids from alpha keto acids by fedbatch fermentation
AU7167591A (en) Treatment of hsv
AU2885689A (en) Novel proteins derived from human alpha2-plasmin inhibitor orproteins similar thereto
AU7422387A (en) Tumor necrosis factor alpha as treatment for infectious diseases
AU7496887A (en) Modified (aa 357/358) -alpha 1-antitrypsin
AU4812190A (en) Use of interleukin-4 for lowering blood-cholesterol levels
AU2473388A (en) Treatment of factor viii inhibitors
AU5178593A (en) Protein fragments of the (pectinatus) bacterium

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry